scispace - formally typeset
Open AccessJournal ArticleDOI

Gastrointestinal Manifestations of Systemic Sclerosis

Reads0
Chats0
TLDR
The current understanding of the pathophysiologic mechanisms of SSc including vasculopathy, endothelial to mesenchymal transformation as well as the autoimmune pathogenetic pathways are presented.
Abstract
Systemic sclerosis (SSc) is a rare autoimmune disease characterized by fibroproliferative alterations of the microvasculature leading to fibrosis and loss of function of the skin and internal organs. Gastrointestinal manifestations of SSc are the most commonly encountered complications of the disease affecting nearly 90% of the SSc population. Among these complications, the esophagus and the anorectum are the most commonly affected. However, this devastating disorder does not spare any part of the gastrointestinal tract (GIT), and includes the oral cavity, esophagus, stomach, small and large bowels as well as the liver and pancreas. In this review, we present the current understanding of the pathophysiologic mechanisms of SSc including vasculopathy, endothelial to mesenchymal transformation as well as the autoimmune pathogenetic pathways. We also discuss the clinical presentation and diagnosis of each part of the GIT affected by SSc. Finally, we highlight the latest developments in the management of this disease, addressing the severe malnutrition that affects this vulnerable patient population and ways to assess and improve the nutritional status of the patients.

read more

Citations
More filters
Journal ArticleDOI

Systemic sclerosis - multidisciplinary disease: clinical features and treatment.

TL;DR: Different clinical features of systemic sclerosis and the profile of autoantibodies are summarized and recent rules and future perspectives in disease management are discussed.
Journal ArticleDOI

Current management of the gastrointestinal complications of systemic sclerosis.

TL;DR: The most commonly occurring clinical scenarios of gastrointestinal involvement in patients with systemic sclerosis as they present to the gastroenterologist are described, with recommendations for the suggested assessment protocol and therapy in each situation.
Journal ArticleDOI

Ongoing clinical trials and treatment options for patients with systemic sclerosis–associated interstitial lung disease

TL;DR: Newer agents targeting the pathogenic mechanisms underlying SSc-ILD, including fibrotic and inflammatory pathways, lymphocytes, cell–cell and cell–extracellular membrane interactions, hold promise for better treatment outcomes, including improved lung function, patient-related outcomes and quality of life.
Journal ArticleDOI

Intestinal Involvement in Systemic Sclerosis: A Clinical Review.

TL;DR: Multidisciplinary approach of intestinal manifestations in SSc by gastroenterologists and rheumatologists is required for optimum management.
Journal ArticleDOI

Evaluation and management of esophageal manifestations in systemic sclerosis.

TL;DR: Buspirone, a 5-hydroxytryptamine 1A receptor agonist, could be a putative therapeutic option, as it was found to exert a significant beneficial effect in SSc patients with esophageal involvement, including emerging therapeutic modalities.
References
More filters
Journal Article

Development and evaluation of the Oral Health Impact Profile.

TL;DR: The Oral Health Impact Profile offers a reliable and valid instrument for detailed measurement of the social impact of oral disorders and has potential benefits for clinical decision-making and research.
Journal Article

EASL Clinical Practice Guidelines: management of cholestatic liver diseases

TL;DR: The clinical care for patients with cholestatic liver diseases has advanced considerably during recent decades thanks to growing insight into pathophysiological mechanisms and remarkable methodological and technical developments in diagnostic procedures as well as therapeutic and preventive approaches.
Journal ArticleDOI

Primary Biliary Cirrhosis

TL;DR: PBC is a chronic cholestatic liver disease characterized by high-titer serum antimitochondrial autoantibodies (AMAs) and autoimmune-mediated destruction of small and medium-sized intrahepatic bile ducts as discussed by the authors.
Related Papers (5)